Exelixis' Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX (Cabozantinib) for Advanced Renal Cell Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr 25, 2019--Exelixis, Inc. (Nasdaq: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the c…
